The creatinine measurement market was valued at US$ 384.69 million in 2019 and is projected to reach US$ 705.96 million by 2027; it is expected to grow at a CAGR of 8.0% from 2020 to 2027.
Factors driving the creatinine measurement market are increasing prevalence of chronic kidney disorders (CKD) and growing prevalence of CKD among the geriatric population. However, a gradual shift toward novel biomarkers is among the major factor restraining the market growth.
There is the growing prevalence of chronic kidney diseases. According to the American Society of Nephrology (ASN), several ongoing recent advancements in molecular diagnostics are supporting the management of patients suffering from kidney-related disorders. Developments in the fields such as nucleic acid amplification and detection, proteomics, genomic analysis, and metabolomics have enhanced several molecular diagnostic assays. Further, the measurement of creatinine concentration in serum or plasma is a widely used procedure in clinical chemistry to assess the functioning of kidneys. There are different levels of CKD, and based on these stages, the creatinine levels can provide a comprehensive analysis of kidneys. Creatinine markers are used to determine the glomerular filtration rate, an essential parameter for diagnosing chronic kidney disease. Owing to its efficiency in the analysis of kidney function, Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended the use of creatinine measurement for kidney screening in 2012. Therefore, increasing chronic kidney disorders, coupled with benefits of creatinine measurement to understand the condition of kidneys, is likely to boost the demand for creatinine measurement devices during the forecast period.
The global creatinine measurement market has been segmented by product, type, sample type, and end user. The creatinine measurement market, by product, is segmented into kits and reagents. The reagent segment held a larger share of the market in 2019. The segment is also anticipated to register a higher CAGR in the market during the forecast period. Based on sample type, the market is segmented into blood and urine. The blood segment held a larger share of the market in 2019 and is estimated to register a higher CAGR during the forecast period. Based on end user, the creatinine measurement market is segmented into hospital, diagnostic laboratories, and others. Diagnostic laboratories held the largest share of the market in 2019, and the segment is further expected to register the fastest CAGR during 2020–2027.
The study considers interactions with a few of the prominent primary participants from leading organizations; different secondary sources referred to for preparing this report are Food and Drug Administration, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Kidney Foundation, and Saudi Society of Nephrology and Transplantation.
Reasons to Buy:
Factors driving the creatinine measurement market are increasing prevalence of chronic kidney disorders (CKD) and growing prevalence of CKD among the geriatric population. However, a gradual shift toward novel biomarkers is among the major factor restraining the market growth.
There is the growing prevalence of chronic kidney diseases. According to the American Society of Nephrology (ASN), several ongoing recent advancements in molecular diagnostics are supporting the management of patients suffering from kidney-related disorders. Developments in the fields such as nucleic acid amplification and detection, proteomics, genomic analysis, and metabolomics have enhanced several molecular diagnostic assays. Further, the measurement of creatinine concentration in serum or plasma is a widely used procedure in clinical chemistry to assess the functioning of kidneys. There are different levels of CKD, and based on these stages, the creatinine levels can provide a comprehensive analysis of kidneys. Creatinine markers are used to determine the glomerular filtration rate, an essential parameter for diagnosing chronic kidney disease. Owing to its efficiency in the analysis of kidney function, Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended the use of creatinine measurement for kidney screening in 2012. Therefore, increasing chronic kidney disorders, coupled with benefits of creatinine measurement to understand the condition of kidneys, is likely to boost the demand for creatinine measurement devices during the forecast period.
The global creatinine measurement market has been segmented by product, type, sample type, and end user. The creatinine measurement market, by product, is segmented into kits and reagents. The reagent segment held a larger share of the market in 2019. The segment is also anticipated to register a higher CAGR in the market during the forecast period. Based on sample type, the market is segmented into blood and urine. The blood segment held a larger share of the market in 2019 and is estimated to register a higher CAGR during the forecast period. Based on end user, the creatinine measurement market is segmented into hospital, diagnostic laboratories, and others. Diagnostic laboratories held the largest share of the market in 2019, and the segment is further expected to register the fastest CAGR during 2020–2027.
The study considers interactions with a few of the prominent primary participants from leading organizations; different secondary sources referred to for preparing this report are Food and Drug Administration, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Kidney Foundation, and Saudi Society of Nephrology and Transplantation.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the creatinine measurement market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global creatinine measurement market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Creatinine Measurement - Market Landscape
5. Creatinine Measurement - Key Market Dynamics
6. Creatinine Measurement Market - Global Analysis
7. Creatinine Measurement Market Analysis - By Product
8. Creatinine Measurement Market - By Type
9. Creatinine Measurement Market - By Sample Type
10. Creatinine Measurement Market Analysis - By End User
11. Creatinine Measurement Market - Geographic Analysis
12. Creatinine Measurement Market- Industry Landscape
13. Creatinine Measurement Market - Key Company Profiles
14. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Siemens Healthcare Gmbh
- Abbott
- Cayman Chemical
- Thermo Fisher Scientific Inc.
- Fujifilm Wako Pure Chemical Corporation
- Randox Laboratories Ltd
- F. Hoffmann-La Roche Ltd
- Danaher (Beckman Coulter)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Maccura Biotechnology Co., Ltd.
- Diazyme Laboratories, Inc
- Dialab Gmbh
- Beijing Jiuqiang Biotechnology Co., Ltd.
- Beijing Leadman Biochemistry
- Shanghai Fosun Pharmaceutical Group Co., Ltd.
